The COVID-19 vaccine developed by the UK pharmaceutical company AstraZeneca and Oxford University has achieved a “formula for success” for effectiveness, the company’s managing director said on Sunday. The vaccine, which is currently being evaluated by the UK’s Independent Medicines Agency, offers “100% protection” against serious COVID illnesses that require hospitalization, Pascal Soriot said in an interview with the Sunday Times newspaper. He added that he believes the studies will show his company has achieved vaccine efficacy equivalent to Pfizer-BioNTech at 95% and Moderna at 94.5%. “We believe we have found the formula for success and how we can achieve the effectiveness that is present in all after two doses,” said the CEO, saying that the data would be published “at some point”. The UK government announced on December 23 that the vaccine developers Oxford AstraZeneca had submitted their data to the Medicines and Health Products Regulatory Authority (MHRA) for approval for mass use.